| Name | Title | Contact Details |
|---|
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that `nature operates in the shortest way possible`.